Penn Seeks to Make CAR T-Cell Therapy Work in Solid Tumor Disease – OncLive
|
Penn Seeks to Make CAR T-Cell Therapy Work in Solid Tumor Disease
OncLive Chimeric antigen receptor (CAR) T-cell therapy for hematological malignancies took a huge step forward this summer with the FDA approval of Novartis' tisagenlecleucel (Kymriah) for relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL … |
